Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial

• Egile Nagusiak: Enikö Sonkoly (Egilea), Julia-Tatjana Maul (Egilea), Matteo Megna (Egilea), Patricia Gorecki (Egilea), Edmée Crombag (Egilea), Jozefien Buyze (Egilea), Laura Savage (Egilea)
• Formatua: Liburua
• Argitaratua: Medical Journals Sweden, 2024-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Scalp psoriasis affects approximately 80% of patients with psoriasis and can negatively impact their quality of life. This post hoc analysis of the VOYAGE 2 Phase III randomized clinical trial evaluated scalp response to guselkumab treatment and its association with skin response and patient-reporte...